1-4 of 4
Oana Brosteanu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1420.
https://doi.org/10.1182/blood-2019-127865
Published: 2019
Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali
Journal: Blood
Blood (2018) 132 (Supplement 1): 83.
https://doi.org/10.1182/blood-2018-99-115790
Published: 2018
Journal Articles

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, M Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schulze, Song-Yau Wang, Michael Cross, PhD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali
Journal: Blood
Blood (2017) 130 (Supplement 1): 1334.
https://doi.org/10.1182/blood.V130.Suppl_1.1334.1334
Published: 2017
Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, Mathias Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schultze, MD, Song-Yau Wang, MD, Oana Brosteanu, PhD, Dietger Niederwieser, MD
Journal: Blood
Blood (2015) 126 (23): 1346.
https://doi.org/10.1182/blood.V126.23.1346.1346
Published: 2015